Overview of the methods and therapies for the primary prevention of variceal bleeding.
Patients with cirrhosis develop varices at a rate of 5% per year, and a third of patients with high-risk varices will bleed. The mortality associated with variceal haemorrhage is typically 20%, and still exceeds that of myocardial infarction. Current options to prevent the first variceal bleed include noncardioselective beta-blockers or variceal band ligation. In patients with medium-to-large esophageal varices, both therapies reduce the risk of bleeding by 50% or more. The choice of therapy should take into account patient choice and local availability; although for most patients drug therapy is the preferred first-line treatment. There has been recent interest in carvedilol, with promising initial data. Further studies are necessary before universal recommendation. There is no role for drug therapy in patients without varices, and the use of beta-blockers for patients with small varices is controversial.
Tripathi
Dhiraj
D
Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham B152TH, UK. d.tripathi@bham.ac.uk
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016099:Endoscopy, Gastrointestinal / Q000009:adverse effects; D004932:Esophageal and Gastric Varices / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D006801:Humans; D008026:Ligation; D018579:Patient Selection; D018570:Risk Assessment; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists